CDXC Chromadex Corp
2,817
$3.38
$0.04
(1.17%)
| Watchers | 2,817 |
| 52-Wk Low | $1.25 |
| 52-Wk High | $4.65 |
| Market Cap | $255.32M |
| Volume | 170,679.00 |
| 52-Wk High | $4.65 |
| 52-Wk Low | $1.25 |
ChromaDex Corporation Reports First Quarter 2024 Financial ResultsBusiness Wire • 5 days ago
ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2024. First Quarter 2024 Financial and Recent Operational Highlights Total net sales were $22.2 million, with...
Share to Feed
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces an ingredient partnership with Solgar, a Nestl Health Science...
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship consumer supplement, Tru Niagen, is now...
CDXC's total volume now sits at 628.2K. The +1.32% price change was insignificant, leaving IBM's price at $3.84...
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen product portfolio is now third-party...
ChromaDex Co. (NASDAQ:CDXC Get Free Report) was the target of a large decline in short interest in February. As of February 29th, there was short interest totalling 1,210,000 shares, a...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
ChromaDex GAAP EPS of $0.00 beats by $0.02, revenue of $21.2M beats by $0.46M...
ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results. Fourth Quarter 2023 and Recent Highlights Total net sales of $21.2 million, with $17.6 million...
Analysts at StockNews.com started coverage on shares of ChromaDex (NASDAQ:CDXC Get Free Report) in a note issued to investors on Sunday. The brokerage set a strong-buy rating on...